Serum anti-p53 antibodies in gastric adenocarcinoma patients are associated with poor prognosis, lymph node metastasis and poorly differentiated nuclear grade
1999
Serum anti-p53 antibodies and gastric cancer prognosis
Sample size: 501
publication
Evidence: moderate
Author Information
Author(s): Wu C-W, Lin Y-Y, Chen G-D, Chi C-W, Carbone D P, Chen J-Y
Primary Institution: Institute of Biomedical Sciences, Academia Sinica
Hypothesis
The presence of serum anti-p53 antibodies in gastric adenocarcinoma patients is associated with poor prognosis and other clinical factors.
Conclusion
The study found that serum anti-p53 antibodies are linked to worse outcomes in gastric cancer patients.
Supporting Evidence
- 11.2% of gastric cancer patients had anti-p53 antibodies.
- No anti-p53 antibodies were found in cancer-free individuals.
- The presence of these antibodies was associated with higher nuclear grade tumors.
- Patients with anti-p53 antibodies had a negative association with survival.
Takeaway
Doctors can check for certain antibodies in the blood of stomach cancer patients to see if they might have a more serious form of the disease.
Methodology
The study examined serum samples from 501 gastric cancer patients for anti-p53 antibodies using immunoblotting analysis.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website